BCA
TCRR

Berman Capital Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Berman Capital Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$0 Hold
70
– – ﹤0.01% 2278
2021
Q2 		$1K Hold
70
– – ﹤0.01% 1849
2021
Q1 		$1K Hold
70
– – ﹤0.01% 1730
2020
Q4 		$2K Hold
70
– – ﹤0.01% 1463
2020
Q3 		$1K Hold
70
– – ﹤0.01% 1548
2020
Q2 		$1K Buy
+70
New +$807 ﹤0.01% 1550

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Berman Capital Advisors's TCRR Position: Q3 2021 in Review

Berman Capital Advisors held its TCR2 Therapeutics Inc. Common Stock (TCRR) position steady in Q3 2021 at 70 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2278.

Berman Capital Advisors first reported a position in TCRR in Q2 2020 and has held it in 6 quarters since. The position peaked at $2K in Q4 2020. 117 funds tracked by Wall St. Rank hold TCRR as of Q3 2021.

  • Berman Capital Advisors held 70 shares of TCR2 Therapeutics Inc. Common Stock worth $0 as of Q3 2021.
  • Berman Capital Advisors left its TCR2 Therapeutics Inc. Common Stock share count unchanged in Q3 2021.
  • TCR2 Therapeutics Inc. Common Stock made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2278 holding.
  • Berman Capital Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and has held it in 6 quarters since.
  • Berman Capital Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $2K in Q4 2020.
  • 117 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.